Contributions
Abstract: P1061
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Introduction: The North American Imaging in Multiple Sclerosis (NAIMS) Cooperative was formed with the goal of developing sensitive and reliable imaging-based surrogates for disease progression in MS. A standardized quantitative imaging protocol which is sensitive and tailored to MS pathology will facilitate more rapid data collection across multiple sites.
Methods: A subject with clinically stable relapsing-remitting MS travelled to seven North American sites and underwent two distinct 3 Tesla MRI sessions at each site. Informed consent was obtained at each site. Whole brain resting state fMRI (rsFMRI) was acquired in 4:28 min (repetition time=1s, 256 volumes, multiband=4, 2.0mm isotropic). A network of five automated regions of interest were placed in left/right inferior parietal lobule (L/RIPL), left/right middle frontal gyrus (L/RMFG), and bilateral posterior cingulate gyrus (BiPCC), and preprocessed time courses were transformed to correlation matrices and converted to Fisher"s z. Intrasite (Pearson"s r) and intersite (intraclass correlation coefficient [ICC]) measures of agreement were calculated over region-to-region correlation scores.
Results: Imaging sessions were completed between October 2015 and February 2016. Spatial signal-to-noise ratios (SNR) across six sites (one site was an outlier) and sessions varied 24%. Temporal SNR varied 412% over seven sites. Slice orientation was the most notable acquisition difference between sites. Motion decreased between the first and second sessions at six out of seven sites. Intrasite correlation measurements across the network were in agreement at each site (r(8)=0.65-0.98, median Fisher"s z=1.472); however, intersite agreement was poor to moderate (ICC =0.402).
Discussion: The multiband rsFMRI protocol yielded high interregional correlations within each session, and high reproducibility within each site. However, intersite agreement was very poor and site-specific measures inversely correlated with temporal and spatial SNR, suggesting a role for noise in between-site variance. The degree of motion correction was variable between sites and motion may be the cause of temporal noise. Despite intersite variance, measurements taken with this sequence yielded consistent pairwise correlations relative to one another in the network. Relative or mean-centered correlation measures within a network and within scan may be more reliable than absolute measures of network correlation when using multisite data.
Disclosure: Daniel Schwartz is funded by Race to Erase MS Fund and has nothing to disclose.
Ian Tagge is funded by the Race to Erase MS Fund and has nothing to disclose.
William Rooney is funded by the Race to Erase MS Fund and has nothing to disclose.
Rohit Bakshi is funded by the Race to Erase MS Fund and has received consulting fees from AbbVie, EMD Serono, Genentech, and Novartis, received research support from Biogen, EMD-Serono, Novartis, and Sanofi-Genzyme, and serves as Editor-in-Chief of the Journal of Neuroimaging.
Govind Nair is funded by Intramural Research Program, NINDS and has nothing to disclose.
Peter Calabresi is funded by NIH R01 NS082347 - Imaging neurodegeneration in multiple sclerosis, and has received grants to Johns Hopkins from Biogen, Novartis, and MedImmune, and has received honoraria for consulting from Vertex.
John Grinstead is a Siemens Healthcare employee and has nothing to disclose.
Roland Henry receives funding from NIH, DOD, and Roche/Genentech, and nothing to disclose.
Todd Constable receives no funding and has nothing to disclose.
Jiwon Oh has received research funding from Multiple Sclerosis Society of Canada, Sanofi- Genzyme, and Biogen-Idec, and has received fees for consulting or speaking from EMD-Serono, Genzyme, Biogen-Idec, Novartis, Teva, and Roche.
Nico Papinutto has no funding and nothing to disclose.
Daniel Pelletier has no funding and has received consulting honoraria from Biogen, Sanofi-Genzyme, Novartis, EMD-Serono, Vertex, and Roche.
Daniel S. Reich receives research funding from Intramural Research Program of NINDS, Myelin Repair Foundation, and Vertex Pharmaceuticals and has nothing to disclose.
Nancy Sicotte receives funding from National MS Society and Guthy-Jackson Charitable Foundation and has nothing to disclose.
William Stern receives no funding and has nothing to disclose.
Jack Simon receives funding from Race to Erase MS and has nothing to disclose.
Abstract: P1061
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Introduction: The North American Imaging in Multiple Sclerosis (NAIMS) Cooperative was formed with the goal of developing sensitive and reliable imaging-based surrogates for disease progression in MS. A standardized quantitative imaging protocol which is sensitive and tailored to MS pathology will facilitate more rapid data collection across multiple sites.
Methods: A subject with clinically stable relapsing-remitting MS travelled to seven North American sites and underwent two distinct 3 Tesla MRI sessions at each site. Informed consent was obtained at each site. Whole brain resting state fMRI (rsFMRI) was acquired in 4:28 min (repetition time=1s, 256 volumes, multiband=4, 2.0mm isotropic). A network of five automated regions of interest were placed in left/right inferior parietal lobule (L/RIPL), left/right middle frontal gyrus (L/RMFG), and bilateral posterior cingulate gyrus (BiPCC), and preprocessed time courses were transformed to correlation matrices and converted to Fisher"s z. Intrasite (Pearson"s r) and intersite (intraclass correlation coefficient [ICC]) measures of agreement were calculated over region-to-region correlation scores.
Results: Imaging sessions were completed between October 2015 and February 2016. Spatial signal-to-noise ratios (SNR) across six sites (one site was an outlier) and sessions varied 24%. Temporal SNR varied 412% over seven sites. Slice orientation was the most notable acquisition difference between sites. Motion decreased between the first and second sessions at six out of seven sites. Intrasite correlation measurements across the network were in agreement at each site (r(8)=0.65-0.98, median Fisher"s z=1.472); however, intersite agreement was poor to moderate (ICC =0.402).
Discussion: The multiband rsFMRI protocol yielded high interregional correlations within each session, and high reproducibility within each site. However, intersite agreement was very poor and site-specific measures inversely correlated with temporal and spatial SNR, suggesting a role for noise in between-site variance. The degree of motion correction was variable between sites and motion may be the cause of temporal noise. Despite intersite variance, measurements taken with this sequence yielded consistent pairwise correlations relative to one another in the network. Relative or mean-centered correlation measures within a network and within scan may be more reliable than absolute measures of network correlation when using multisite data.
Disclosure: Daniel Schwartz is funded by Race to Erase MS Fund and has nothing to disclose.
Ian Tagge is funded by the Race to Erase MS Fund and has nothing to disclose.
William Rooney is funded by the Race to Erase MS Fund and has nothing to disclose.
Rohit Bakshi is funded by the Race to Erase MS Fund and has received consulting fees from AbbVie, EMD Serono, Genentech, and Novartis, received research support from Biogen, EMD-Serono, Novartis, and Sanofi-Genzyme, and serves as Editor-in-Chief of the Journal of Neuroimaging.
Govind Nair is funded by Intramural Research Program, NINDS and has nothing to disclose.
Peter Calabresi is funded by NIH R01 NS082347 - Imaging neurodegeneration in multiple sclerosis, and has received grants to Johns Hopkins from Biogen, Novartis, and MedImmune, and has received honoraria for consulting from Vertex.
John Grinstead is a Siemens Healthcare employee and has nothing to disclose.
Roland Henry receives funding from NIH, DOD, and Roche/Genentech, and nothing to disclose.
Todd Constable receives no funding and has nothing to disclose.
Jiwon Oh has received research funding from Multiple Sclerosis Society of Canada, Sanofi- Genzyme, and Biogen-Idec, and has received fees for consulting or speaking from EMD-Serono, Genzyme, Biogen-Idec, Novartis, Teva, and Roche.
Nico Papinutto has no funding and nothing to disclose.
Daniel Pelletier has no funding and has received consulting honoraria from Biogen, Sanofi-Genzyme, Novartis, EMD-Serono, Vertex, and Roche.
Daniel S. Reich receives research funding from Intramural Research Program of NINDS, Myelin Repair Foundation, and Vertex Pharmaceuticals and has nothing to disclose.
Nancy Sicotte receives funding from National MS Society and Guthy-Jackson Charitable Foundation and has nothing to disclose.
William Stern receives no funding and has nothing to disclose.
Jack Simon receives funding from Race to Erase MS and has nothing to disclose.